Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
- 1 February 2021
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 397 (10274), 592-604
- https://doi.org/10.1016/s0140-6736(21)00228-2
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
- Regeneron Pharmaceuticals
This publication has 28 references indexed in Scilit:
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Lung Cancer in Women, a Different Disease: Survival Differences by Sex in TurkeyAsian Pacific Journal of Cancer Prevention, 2015
- A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancerThorax, 2015
- Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trialsLung Cancer, 2014
- Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal miceProceedings of the National Academy of Sciences of the United States of America, 2014
- Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genesProceedings of the National Academy of Sciences of the United States of America, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Interpreting the significance of changes in health-related quality-of-life scores.Journal of Clinical Oncology, 1998